for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Strongbridge Biopharma plc

SBBP.OQ

Latest Trade

1.78USD

Change

0.01(+0.56%)

Volume

9,938

Today's Range

1.75

 - 

1.80

52 Week Range

1.43

 - 

5.68

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Strongbridge Biopharma Plc Announces Additional Steps To Improve Operational Efficiencies

Nov 18 (Reuters) - Strongbridge Biopharma plc <SBBP.O>::STRONGBRIDGE BIOPHARMA PLC ANNOUNCES ADDITIONAL STEPS TO IMPROVE OPERATIONAL EFFICIENCIES AND APPOINTS NEW LEAD INDEPENDENT DIRECTOR.STRONGBRIDGE BIOPHARMA PLC - ELIMINATING APPROXIMATELY 15 POSITIONS THROUGH A REDUCTION IN HEADCOUNT.STRONGBRIDGE BIOPHARMA - 15 POSITIONS REDUCTION IS IN ADDITION TO PREVIOUSLY ANNOUNCED ELIMINATION OF COMMERCIAL COSTS RELATED TO MACRILEN.STRONGBRIDGE BIOPHARMA PLC - TOTAL REDUCTION OF OVERALL EMPLOYEE HEADCOUNT IS ABOUT 38 POSITIONS, OR 34%.STRONGBRIDGE BIOPHARMA PLC - INTENDS TO OPTIMIZE RESOURCES FOR COMPLETING DEVELOPMENT OF RECORLEV, GROW KEVEYIS.STRONGBRIDGE BIOPHARMA PLC - EXPECTS TO REALIZE ESTIMATED ANNUALIZED COST SAVINGS OF ABOUT $4.2 MILLION STARTING IN 2020 BASED UPON JOB ELIMINATION.STRONGBRIDGE BIOPHARMA PLC - NOW BELIEVES IT CAN FUND OPERATIONS AS CURRENTLY PLANNED THROUGH Q2 OF 2021.STRONGBRIDGE BIOPHARMA PLC - CO ESTIMATES THAT IT WILL INCUR ABOUT $1.4 MILLION FOR SEVERANCE & OTHER COSTS RELATED TO JOB CUTS.STRONGBRIDGE BIOPHARMA PLC - ON TRACK TO MEET/EXCEED TOP END OF FY KEVEYIS REVENUE GUIDANCE RANGE OF $18 MILLION - $20 MILLION.

Strongbridge Biopharma Reports Third Quarter 2019 Financial Results

Nov 7 (Reuters) - Strongbridge Biopharma plc <SBBP.O>::REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 NON-GAAP LOSS PER SHARE $0.25.Q3 GAAP LOSS PER SHARE $0.25.Q3 REVENUE $5.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $5.1 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES DATA.

Strongbridge - On-Track To Meet Or Exceed Top End Of FY Keveyis Revenue Guidance Of $18 Mln-$20 Mln

Nov 7 (Reuters) - Strongbridge Biopharma plc <SBBP.O>::STRONGBRIDGE BIOPHARMA PLC - REMAINS ON-TRACK TO MEET OR EXCEED TOP END OF FULL-YEAR KEVEYIS REVENUE GUIDANCE OF $18 MILLION TO $20 MILLION.STRONGBRIDGE BIOPHARMA PLC - CASH SUFFICIENT TO FUND OPERATIONS THROUGH Q2 2021.

Strongbridge Biopharma Announces CEO Transition Plan And Provides Preliminary Q3 Results

Nov 5 (Reuters) - Strongbridge Biopharma plc <SBBP.O>::STRONGBRIDGE BIOPHARMA PLC ANNOUNCES CEO TRANSITION PLAN AND PROVIDES PRELIMINARY THIRD QUARTER 2019 FINANCIAL RESULTS AND CORPORATE UPDATES.STRONGBRIDGE BIOPHARMA PLC - MATTHEW PAULS IS STEPPING DOWN AS PRESIDENT, CHIEF EXECUTIVE OFFICER (CEO) AND DIRECTOR, EFFECTIVE IMMEDIATELY.STRONGBRIDGE BIOPHARMA PLC - JOHN H. JOHNSON HAS ASSUMED POSITION OF EXECUTIVE CHAIRMAN, EFFECTIVE IMMEDIATELY.STRONGBRIDGE BIOPHARMA PLC - JOHN H. JOHNSON WILL LEAD ORGANIZATION WHILE BOARD CONDUCTS A FORMAL SEARCH TO IDENTIFY A NEW CEO.STRONGBRIDGE BIOPHARMA PLC - ANTICIPATES THAT IT WILL REPORT KEVEYIS NET PRODUCT SALES OF $5.7 MILLION DURING Q3 OF 2019, A 36 PERCENT INCREASE.STRONGBRIDGE BIOPHARMA PLC - REMAINS ON TRACK TO MEET OR EXCEED TOP END OF FULL-YEAR 2019 KEVEYIS REVENUE GUIDANCE OF $18 MILLION TO $20 MILLION.STRONGBRIDGE - EXPECTS TO REPORT QUARTER-END CASH AND CASH EQUIVALENTS OF APPROXIMATELY $79.6 MILLION, AND NO OUTSTANDING DEBT, AS OF SEPTEMBER 30, 2019.

Strongbridge Biopharma Announces Recorlev (Levoketoconazole) Phase 3 Sonics Data

Sept 19 (Reuters) - Strongbridge Biopharma plc <SBBP.O>::STRONGBRIDGE BIOPHARMA PLC ANNOUNCES RECORLEV™ (LEVOKETOCONAZOLE) PHASE 3 SONICS DATA PUBLISHED IN THE LANCET DIABETES & ENDOCRINOLOGY.STRONGBRIDGE BIOPHARMA PLC - RECORLEV WAS GENERALLY WELL-TOLERATED, WITH NO UNEXPECTED SAFETY SIGNALS OBSERVED.STRONGBRIDGE BIOPHARMA PLC - RECORLEV RESULTED IN SUSTAINED IMPROVEMENTS IN URINARY FREE CORTISOL (UFC) AND PROVIDED CLINICAL BENEFIT.

Strongbridge Biopharma Announces Key Leadership Appointments To Support Next Stage Of Growth

Aug 13 (Reuters) - Strongbridge Biopharma plc <SBBP.O>::STRONGBRIDGE BIOPHARMA ANNOUNCES KEY LEADERSHIP APPOINTMENTS TO SUPPORT NEXT STAGE OF GROWTH.STRONGBRIDGE BIOPHARMA PLC - ROBERT LUTZ PROMOTED TO CHIEF FINANCIAL OFFICER.STRONGBRIDGE BIOPHARMA PLC - DAVID GILL APPOINTED TO BOARD OF DIRECTORS.STRONGBRIDGE BIOPHARMA PLC - RICHARD S. KOLLENDER APPOINTED TO CHIEF OPERATING OFFICER.STRONGBRIDGE BIOPHARMA PLC - BRIAN DAVIS, CURRENT CHIEF FINANCIAL OFFICER, IS LEAVING COMPANY.STRONGBRIDGE BIOPHARMA PLC - ALL MANAGEMENT AND BOARD CHANGES WILL BECOME EFFECTIVE ON SEPTEMBER 3, 2019.

Strongbridge Biopharma Reports Second Quarter 2019 Revenue Of $6.1 Mln

July 31 (Reuters) - Strongbridge Biopharma plc <SBBP.O>::REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 NON-GAAP LOSS PER SHARE $0.24.Q2 GAAP LOSS PER SHARE $0.15.Q2 EARNINGS PER SHARE ESTIMATE $-0.34 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $18 MILLION TO $20 MILLION.COMPANY ON TRACK TO MEET FULL-YEAR 2019 KEVEYIS REVENUE GUIDANCE OF $18 TO $20 MILLION.QTRLY TOTAL REVENUE $6.1 MILLION VERSUS $4.3 MILLION.Q2 REVENUE VIEW $4.7 MILLION -- REFINITIV IBES DATA.STRONGBRIDGE BIOPHARMA - ENROLLMENT IN PHASE 3 LOGICS STUDY FOR RECORLEV PROGRESSING WITH TOP-LINE DATA ANTICIPATED AT END OF Q1 2020.

Strongbridge Biopharma Reports Top-Line Results from Extended Phase 3 Study of RECORLEV for Treatment of Endogenous Cushing's Syndrome

March 11 (Reuters) - Strongbridge Biopharma plc <SBBP.O>::STRONGBRIDGE BIOPHARMA PLC ANNOUNCES TOP-LINE RESULTS FROM EXTENDED EVALUATION PHASE OF THE PIVOTAL PHASE 3 SONICS STUDY OF RECORLEV™ (LEVOKETOCONAZOLE) FOR THE POTENTIAL TREATMENT OF ENDOGENOUS CUSHING’S SYNDROME.STRONGBRIDGE BIOPHARMA - EXTENDED EVALUATION PHASE MEETS OBJECTIVE OF SHOWING POSITIVE LONG-TERM BENEFIT-RISK PROFILE OF RECORLEV (LEVOKETOCONAZOLE).STRONGBRIDGE BIOPHARMA PLC - LONG-TERM EFFICACY RESULTS OF RECORLEV™ (LEVOKETOCONAZOLE) CONTINUE TO DEMONSTRATE CLINICALLY MEANINGFUL IMPROVEMENTS.STRONGBRIDGE BIOPHARMA - NO PATIENTS EXPERIENCED INCREASE IN ALT OR AST OF GREATER THAN 3 TIMES UPPER LIMIT OF NORMAL IN EXTENDED EVALUATION PHASE.STRONGBRIDGE BIOPHARMA - RECORLEV GENERALLY WELL-TOLERATED DURING EXTENDED EVALUATION PHASE AND NO NEW DRUG-RELATED SAFETY SIGNALS WERE OBSERVED.

Strongbridge Biopharma Q4 Non-GAAP Loss Per Share $0.46

Feb 26 (Reuters) - Strongbridge Biopharma plc <SBBP.O>::REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 NON-GAAP LOSS PER SHARE $0.46.Q4 GAAP EARNINGS PER SHARE $1.73.Q4 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $18 MILLION TO $20 MILLION.COMPANY ANTICIPATES POSITIVE KEVEYIS CONTRIBUTION MARGIN BY END OF Q1 OF 2020.QTRLY TOTAL REVENUES $4.5 MILLION VERSUS ABOUT $3 MILLION.

Strongbridge Biopharma Reports Q4 Non-Gaap Loss $0.46 Per Share

Feb 26 (Reuters) - Strongbridge Biopharma plc <SBBP.O>::SEES FY 2019 KEVEYIS(DICHLORPHENAMIDE)REVENUE $18 MILLION TO $20 MILLION.REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 NON-GAAP LOSS PER SHARE $0.46.Q4 GAAP EARNINGS PER SHARE $1.73.Q4 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA.COMPANY ANTICIPATES POSITIVE KEVEYIS CONTRIBUTION MARGIN BY END OF Q1 OF 2020.QTRLY TOTAL REVENUES $4.5 MILLION VERSUS ABOUT $3 MILLION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up